Edwards Lifesciences Corp (EW) Q2 2026 Earnings Call Highlights: Strong Sales Growth and Strategic Advancements - GuruFocus
Edwards' 13.6% Q2 TAVR sales growth and Venus Medtech's completed self-expanding pivotal enrollment reflect a market expanding faster than durability data can validate.
Three technique-focused papers signal where operators are spending their cognitive load: a Radiology: Cardiothoracic Imaging review on preprocedural CT for redo TAVR, a European Cardiology review of BASILICA , and a Future Cardiology review of direct TAVI vs predilatation .
All three are downstream consequences of the ESC 2025 lifetime-management mandate: coronary access, valve-in-valve feasibility, and commissural alignment must be planned at the index procedure.
Edwards Lifesciences Corp (EW) Q2 2026 Earnings Call Highlights: Strong Sales Growth and Strategic Advancements GuruFocus
- Aortic Valve (TAVR/TAVI)· Heart failure reviewsA sex-specific perspective on coronary microvascular dysfunction in HFpEF: from vascular to myocardial disease.
- Aortic Valve (TAVR/TAVI)· Herzschrittmachertherapie & ElektrophysiologieImaging phenotypes and substrates in ventricular tachycardia.
- Aortic Valve (TAVR/TAVI)· Future cardiologyOptimizing TAVI strategy: balancing predilatation benefits and direct implantation efficiency.
- Mitral Valve (Repair & Replacement)· Structural heart : the journal of the Heart TeamPreprocedural New York Heart Association Class IV Independently Predicts Mortality After Effective Edge-To-Edge Repair for Primary Mitral Regurgitation.
- Tricuspid Valve (Repair & Replacement)· JACC. Case reportsCryoextraction for Airway Bleeding After Valve-in-Valve Procedure.
- Surgical vs Transcatheter· General thoracic and cardiovascular surgeryA critical appraisal of "A novel survival prediction model after isolated surgical aortic valve replacement in the transcatheter aortic valve replacement era".